Rethinking Employer Coverage for High-Cost Medications

Why It Matters

The shift toward DTE carve‑outs could stabilize employer drug spend and improve workforce health, directly influencing talent retention and productivity.

Key Takeaways

• Health plan costs may rise 9% in 2026
• GLP‑1 drugs drive most prescription cost growth
• 61% of large employers evaluating new pharmacy models
• Direct‑to‑employer carve‑outs can match DTP pricing
• Clinical oversight essential in DTE carve‑out partnerships

Pulse Analysis

Rising health‑benefit expenses are reshaping corporate payroll strategies, with prescription drugs now the primary cost driver. GLP‑1 receptor agonists, once confined to diabetes care, have exploded in demand as weight‑loss solutions, pushing monthly price tags above $1,300. This surge has forced benefits managers to confront budgetary pressures that could erode profit margins and strain employee morale if access to life‑changing medications is limited.

In response, employers are gravitating toward direct‑to‑employer (DTE) carve‑out arrangements, a model that contracts pharmacies to supply high‑cost drugs at negotiated, transparent rates. By aligning cost‑share formulas with real‑world utilization data, DTE carve‑outs can replicate the steep discounts seen in direct‑to‑patient (DTP) programs while maintaining the employer’s role in benefit design. Federal encouragement for price‑lowering partnerships further fuels this transition, positioning carve‑outs as a viable path to cost predictability and broader drug access.

Successful implementation hinges on selecting pharmacy partners that provide clinical expertise, adherence monitoring, and a portfolio of therapeutic options. Employers must ensure that carve‑outs support multiple GLP‑1 products—such as Wegovy, Zepbound, and Ozempic—to accommodate patient variability and physician preference. As the market evolves, DTE carve‑outs promise a sustainable balance between fiscal responsibility and employee health, ultimately safeguarding both corporate bottom lines and workforce productivity.